MNG1174
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.636
- INTERFERON_GAMMA_RESPONSE+0.575
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.339
- PROTEIN_SECRETION+0.339
- INFLAMMATORY_RESPONSE+0.317
- UV_RESPONSE_DN+0.277
- APICAL_JUNCTION+0.221
- MITOTIC_SPINDLE+0.212
- PI3K_AKT_MTOR_SIGNALING+0.210
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.331
- PANCREAS_BETA_CELLS-0.292
- SPERMATOGENESIS-0.277
- ESTROGEN_RESPONSE_LATE-0.255
- KRAS_SIGNALING_DN-0.223
- BILE_ACID_METABOLISM-0.208
- COAGULATION-0.203
- ANGIOGENESIS-0.200
- HYPOXIA-0.180
- P53_PATHWAY-0.161
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1196 | — | — | 0.837 |
| 2 | MNG1199 | — | — | 0.811 |
| 3 | MNG746 | — | — | 0.801 |
| 4 | SRR934780 | — | — | 0.798 |
| 5 | MNG525 | — | — | 0.793 |
| 6 | SRR934808 | — | — | 0.769 |
| 7 | BF513557-1518-4843-9F62-837B557D4CAB | — | — | 0.757 |
| 8 | TCGA-E7-A3X6-01A-12R-A22U-07 | — | — | 0.756 |
| 9 | E35A6AA5-331F-489B-8CE1-9D0BC4CDE119 | — | — | 0.754 |
| 10 | MNG596 | — | — | 0.753 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.636 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.575 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.339 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.339 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.317 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.277 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.221 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.212 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.207 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.202 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.174 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.168 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.168 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.166 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.162 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.154 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.143 | Inavolisib | — uncovered |